Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.22.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Statement of Cash Flows [Abstract]    
Net loss $ (17,851) $ (15,604)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 691 867
Stock-based compensation 1,387 668
Non-cash interest expense 498 156
Non-cash advertising expense 400
Change in fair value of preferred stock warrant liability 744
Non-cash portion of loss on debt extinguishment 161
Forgiveness of PPP loan (2,180)
Loss on disposal of property and equipment 16
Provision for bad debt (54)
Deferred rent 338 (210)
Accounts receivable (4,431) (402)
Prepaid expenses and other current assets (564) (647)
Deposits 105
Accounts payable 1,015 (397)
Accrued expenses and other liabilities 1,499 498
Deferred revenues 799 (72)
Customer deposits (421)
Net cash used in operating activities (18,592) (14,399)
Cash flows from investing activities:    
Purchase of property and equipment (611) (647)
Net cash used in investing activities (611) (647)
Cash flows from financing activities:    
Cash paid in connection with the Merger, net of cash acquired (46)
Payment to unaccredited investors of Augmedix Operating Corporation (22) (555)
Proceeds from sale of common stock 40,000 27,417
Proceeds from exercise of common stock warrants 4
Payment of offering costs in relation to common stock issuance (4,109) (3,159)
Proceeds from exercise of stock options 152 80
Proceeds from issuance of convertible notes payable 500
Proceeds from loan payable 15,000
Proceeds from note payable 2,180
Repayment of note payable (12,966)
Payment of financing costs (232)
Net cash provided by financing activities 37,827 26,417
Effect of exchange rate changes on cash and restricted cash (10) (1)
Net increase in cash and restricted cash 18,614 11,370
Cash and restricted cash at beginning of year 22,973 11,603
Cash and restricted cash at end of year 41,587 22,973
Supplemental disclosure of cash flow information:    
Cash paid during the year for interest 1,613 1,266
Cash paid during the year for taxes 44
Supplemental schedule of non-cash investing and financing activities:    
Conversion of convertible preferred stock to shares of common stock 54,242
Amounts due to unaccredited investors of Augmedix Operating Corporation 32
Financing fees in accrued expenses 5
Fair value of warrants issued in connection with loan 395
Fair value of common stock issued to service provider 600
Property, plant, and equipment in accounts payable $ 91